Skip to main content

Pexidartinib Side Effects

Medically reviewed by Last updated on Oct 30, 2023.

Applies to pexidartinib: oral capsule.


Oral route (Capsule)

Pexidartinib can cause serious and potentially fatal liver injury. Monitor liver tests prior to initiation of pexidartinib and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue pexidartinib based on severity of hepatotoxicity. Pexidartinib is available only through a restricted program called the Turalio Risk Evaluation and Mitigation Strategy (REMS) Program.

Serious side effects of Pexidartinib

Along with its needed effects, pexidartinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pexidartinib:

More common

Less common

Other side effects of Pexidartinib

Some side effects of pexidartinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to pexidartinib: oral capsule.


Very common (10% or more): decreased neutrophils (44%), decreased lymphocytes (38%), de creased hemoglobin (30%), decreased platelets (15%)[Ref]


Very common (10% or more): Eye edema (30%)

Common (1% to 10%): Blurred vision, photophobia, diplopia, reduced visual acuity[Ref]


Very common (10% or more): Increased lactate dehydrogenase (92%), increased cholesterol (44%), decreased phosphate (25%), anorexia (16%)[Ref]


Very common (10% or more): Increased AST (61%), increased ALT (31%), increased ALP (31%)

Common (1% to 10%): Increased bilirubin, cholangitis, hepatotoxicity, liver disorder[Ref]


Very common (10% or more): Fatigue (64%), peripheral edema (20%)

Common (1% to 10%): Pyrexia[Ref]

Nervous system

Very common (10% or more): Dysgeusia/ageusia (26%), neuropathy (e.g., neuropathy peripheral, paresthesia, hypoesthesia, burning sensation) (10%)

Common (1% to 10%): Cognitive disorders (memory impairment, amnesia, confusional state, disturbance in attention, attention deficit/hyperactivity disorder)[Ref]


Very common (10% or more): Hypertension (15%)[Ref]


Very common (10% or more): Hair color changes (67%), rash (e.g., maculopapular rash, rash pruritic, urticaria, erythema, dermatitis acneiform, dermatitis allergic) (28%), pruritus (18%)

Common (1% to 10%): Alopecia, skin pigment changes (hypopigmentation,

depigmentation, discoloration, hyperpigmentation)[Ref]


Very common (10% or more): Vomiting (20%), constipation (12%)

Common (1% to 10%): Dry mouth, stomatitis, mouth ulceration[Ref]


1. Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.